Salt Composition in both
Salt Composition
Amlodipine besylate 10mg(same for both)
You Searched
Strip of 10 tablets
We only sell the best substitute from top brands
Our Recommendation
Ospedan 10mg Tablet 10s
832+ Customers trust this
WHO GMP Certified
Marketed by
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More
Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s
ordinaria.com/ordinaria-com is a (Hospital-wide).Omron 10mg Tablet 10s
Levitra Dosing Tablet 10s
The patient information leaflet ( IFF) is a patient information sheet that provides a user interface for taking tablets. It is available through various pharmaceutical companies. The patient information leaflet includes a few useful features that may be used to improve the function, usefulness, or safety of the tablets. These features include:
EdamQuesting software
BudgetMAPS patient assistance information
EdamPharma user guide
Patient Guide
EdamQuesting is a patient assistance program that enables its users to provide patient information to their companies. The company provides the patient assistance program, which is available in IFF, and has been designed to assist patients with their medication needs. It allows patients to save more by providing patient assistance. EdamPharma provides the patient assistance program for its patients with their medication needs. It enables its users to provide patient information to their companies.
Pfizer, the US-based pharmaceutical company that makes the anti-blood thinner Plavix, said Tuesday that it had received an agreement from the United States Food and Drug Administration to sell its Norvasc tablet as a generic version of the drug Plavix.
Pfizer, the world's top pharmaceutical company, said in a statement that the agreement would be maintained until March 20, after which Pfizer will conduct further studies and market the drug at a lower price.
The pharmaceutical giant said that Pfizer's marketing plan, which includes the sale of Norvasc, would include a reduction in the amount of the drug's active pharmaceutical ingredient (API) in the form of Norvasc.
Pfizer's shares fell 8% to $36.58 on the New York Stock Exchange.
"It was a very good outcome for us as we were able to reach the goal of achieving our goal of selling the drug, we are pleased that we have achieved our target price of $36.00," said Ian Read, Pfizer's chairman and chief executive.
While the company's drug, Norvasc, is a blood thinner, its patent has allowed the drug to be marketed under the name "Ciloxan" or "Amlodipine" as a generic, a name that Pfizer had no prior agreement with the US.
Pfizer's Norvasc patent was last approved in November by the US Food and Drug Administration, but was delayed until it expired in 2011.
Pfizer, which sells the drug in the United States, said on Tuesday that the agreement with the US was "continuous."
Pfizer's patent on Norvasc was recently awarded to the world's top pharmaceutical company, Johnson & Johnson.
Photograph: AlamyPfizer Inc. said that it was pleased by the "good outcome of the litigation and the agreement with the US."
The company, based in Miami, said that it had reached an agreement with the US to buy the rights to Norvasc from Pfizer in the United States and the company was in the process of obtaining a final U. S. agreement.
Pfizer's shares fell 8% to $24.17 in New York.
shares fell 8% to $18.64 on the New York Stock Exchange.The company said that it had received an agreement with the United States to sell the Norvasc drug in the United States and the company was interested in having Pfizer begin marketing the drug at a lower price.
Pfizer's patent on Norvasc was recently awarded to the world's top pharmaceutical company Johnson & Johnson, and it had been approved for marketing in the United States.
Photograph by Alamy/AP/iStock/ShutterstockPfizer's patent was last awarded to the world's top pharmaceutical company, Johnson & Johnson.
The company said that the agreement with the US was "continuous."
Pfizer's Norvasc patent was last awarded to the world's top pharmaceutical company, Johnson & Johnson.
The drug's patent was recently awarded to Pfizer, the world's top drug company and Johnson & Johnson.
In May, Pfizer Inc. said that it had awarded two patents covering Norvasc to Johnson & Johnson and that it was "continuous" to continue marketing the drug in the United States.
Pfizer's patent on Norvasc was awarded to the world's top drug company Johnson & Johnson.
In May, Pfizer said it had awarded two patents covering Norvasc to Johnson & Johnson and that it was "continuous" to continue marketing the drug in the United States.
The drug's patent was awarded to the world's top drug company Johnson & Johnson.
In May, Johnson & Johnson said it had awarded two patents covering Norvasc to Pfizer and that it was "continuous."
Norvasc(amlodipine), also known by its generic name amlodipine, is a widely used calcium channel blocker, primarily prescribed to treat hypertension, angina, or certain types of chest pain. Amlodipine works by blocking calcium channels that are needed for pumping blood across the heart.
Norvasc is available in both tablet and liquid form. It is usually taken once daily, starting on the first day of its use. The recommended starting dose for patients with moderate to severe kidney disease is once daily, at a dosage of 1 mg once daily. This dosage should be carefully monitored and adjusted as necessary, even though the medication is not yet fully effective.
The most common side effects include headache, nausea, vomiting, and dizziness. More serious side effects are rare but can include seizures (convulsions), liver problems, or kidney damage. Patients with moderate to severe kidney disease should not take amlodipine.
It is important to note that amlodipine can interact with certain medications, including blood pressure medications, and certain supplements. Before taking amlodipine, patients should discuss their medical history, including any past or family history of hypertension, angina, or certain cardiovascular disorders, with their healthcare provider. Additionally, patients should discuss the potential side effects of amlodipine with their healthcare provider before starting a new medication, including taking it with certain other medications.
), also known by its generic name amlodipine, is a calcium channel blocker primarily used to treat hypertension and chest pain.
), also known by its generic name amlodipine, is a calcium channel blocker primarily prescribed to treat hypertension and angina. By reducing the effects of calcium channels in the heart, amlodipine helps to reduce the likelihood of developing heart-related issues and the risk of heart disease.
Amlodipine is a calcium channel blocker used to treat hypertension, angina, and certain types of chest pain. Lowering the calcium channel can help reduce symptoms such as chest pain, heart rate, and blood pressure.
Patients should be aware that taking Amlodipine can increase the risk of side effects, such as muscle pain, dizziness, and flushing. If you experience any of these symptoms while taking Amlodipine, stop taking it and contact your healthcare provider immediately. In case you miss a dose, take it as soon as possible and skip the missed dose. Do not double the dose to catch up.
Amlodipine), also known by its generic name amlodipine, is a calcium channel blocker primarily used to treat hypertension and angina. Amlodipine works by inhibiting calcium channels in the heart, which helps to reduce the likelihood of developing heart-related issues and the risk of developing heart-related problems. By reducing the effects of calcium channels in the heart, amlodipine helps to reduce the likelihood of developing heart-related issues and the risk of developing heart disease. Amlodipine is available in both tablet and liquid form.
The market size for Norvasc was valued at USD 1.7 billion in 2023 and is expected to reach USD 3.6 billion by 2032.
The market is expected to be competitive over the forecast period, with its market size estimated at USD 4.7 billion by 2026. The market has a volume estimate of USD 1.3 billion in the forecast period.
The global market for the drug is expected to grow at a CAGR of 6.0% from 2024 to 2030, reaching a market size of USD 1.9 billion by 2032. This growth is driven by the increasing prevalence of conditions related to hypertension, coronary artery disease, and diabetes.
The market is expected to perform well over the forecast period, with a CAGR of 6.0% and a volume estimate of USD 1.7 billion in 2024 and 2032, respectively. However, it is important to note that the market size for Norvasc was significantly impacted by competition from other drugs, which had an average price of USD 0.15 per pill.
The overall market for the drug is expected to grow at a CAGR of 5.0% from 2024 to 2030 and 5.0% from 2032 to 2030.
The drug's market is highly competitive, with a market size estimated at USD 1.9 billion by 2026, which is expected to grow at a CAGR of 6.0% from 2024 to 2030. The market is expected to perform well over the forecast period, with a volume estimate of USD 1.7 billion in 2024 and 2032, respectively. However, it is important to note that the market size for Norvasc was impacted by competition from other drugs, which had an average price of USD 0.15 per pill.
The market is also highly competitive, with a market size estimated at USD 4.7 billion by 2026, which is expected to grow at a CAGR of 6.0% from 2024 to 2030. The market is expected to perform well over the forecast period, with a volume estimate of USD 1.9 billion in 2024 and 2032, respectively.
The global market for the drug is expected to be impacted by a number of factors, including competition from several generic drug manufacturers, price erosion, and the increasing demand for oral medications. The drug has a significant market share and is expected to grow at a CAGR of 6.0% from 2024 to 2030.
The market for the drug is also highly competitive, with a market size estimated at USD 1.9 billion by 2026, which is expected to grow at a CAGR of 6.0% from 2024 to 2030. The market size for Norvasc was also significantly impacted by the competition from other drugs, which had an average price of USD 0.15 per pill.
The global market for the drug is also highly competitive, with a market size estimated at USD 1.9 billion by 2026, which is expected to grow at a CAGR of 6.0% from 2024 to 2030.
The market for the drug is also highly competitive, with a market size estimated at USD 3.8 billion by 2026, which is expected to grow at a CAGR of 6.0% from 2024 to 2030. The market is expected to perform well over the forecast period, with a volume estimate of USD 3.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$17.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Keep out of the reach of childrenDryupharmonysticinformiaHealthylifeOverviewHealthylife is the healthcare provider who regulates the operations of the pharmacy operations of the Our pharmacist helps people obtain prescription medicines through the use of the Healthylife website. Healthylife is a registered Australian pharmacy andreditsCredit is held by the pharmacy operating in the name of the pharmacy. Healthylife is a licensed and regulated Australian pharmacy. Healthylife is a recognized Australia registered and regulated Australian pharmacy. Healthylife is a registered Australian pharmacy. Healthylife is a registered pharmacy. Healthylife is a registered and regulated Australian pharmacy. Healthylife is a registered and regulated pharmacy. Healthylife is a licensed and regulated pharmacy.
Stade de France Pharmacy